- Millendo Therapeutics Appoints Tamara Joseph as General Counsel and Ryan Zeidan as Chief Development Officer
- Millendo Therapeutics Reports Second Quarter 2019 Operating and Financial Results
- Millendo Therapeutics to Participate in August Investor Conferences
- Millendo Therapeutics Announces Departure of Chief Medical Officer
- Millendo Therapeutics to Present at Jefferies 2019 Healthcare Conference
As of last trade
Millendo Therapeutics Inc (MLND:NAQ) traded at 7.17, 8.05% above its 52-week low of 6.64, set on Aug 16, 2019.
6.64Aug 16 201917.34Apr 08 2019
Markit short selling activity
|Market cap||97.51m USD|
|EPS (TTM)||-12.77 |
Data delayed at least 15 minutes, as of Aug 20 2019 19:19 BST.